DE60036388D1 - Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen - Google Patents

Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Info

Publication number: DE60036388D1
Authority: DE; Germany
Prior art keywords: receptor; molecules; antigen; cell; multispecific
Prior art date: 1999-07-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE60036388T

Other languages

English (en)

Inventor

Yashwant M Deo

Joel Goldstein

Robert Graziano

Tibor Keler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

ER Squibb and Sons LLC

Original Assignee

Medarex LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-07-30

Filing date

2000-07-25

Publication date

2007-10-25

1999-07-30 Priority claimed from US09/364,088 external-priority patent/US6365161B1/en

2000-07-25 Application filed by Medarex LLC filed Critical Medarex LLC

2007-10-25 Application granted granted Critical

2007-10-25 Publication of DE60036388D1 publication Critical patent/DE60036388D1/de

2020-07-26 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1808—Epidermal growth factor [EGF] urogastrone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Immunology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Oncology (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
AIDS & HIV (AREA)
Epidemiology (AREA)
Toxicology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

DE60036388T 1999-07-30 2000-07-25 Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen Expired - Lifetime DE60036388D1 (de)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US09/364,088 US6365161B1 (en)	1995-06-07	1999-07-30	Therapeutic compounds comprised of anti-FC receptor binding agents
US52327900A	2000-03-10	2000-03-10
PCT/US2000/020158 WO2001009186A2 (en)	1999-07-30	2000-07-25	Therapeutic compounds comprised of anti-fc receptor binding agents

Publications (1)

Publication Number	Publication Date
DE60036388D1 true DE60036388D1 (de)	2007-10-25

Family

ID=27002335

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE60036388T Expired - Lifetime DE60036388D1 (de)	1999-07-30	2000-07-25	Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen

Country Status (12)

Country	Link
EP (1)	EP1212366B1 (de)
JP (2)	JP4308470B2 (de)
KR (1)	KR100816958B1 (de)
CN (1)	CN1268645C (de)
AT (1)	ATE373017T1 (de)
AU (1)	AU779116B2 (de)
CA (1)	CA2381565A1 (de)
DE (1)	DE60036388D1 (de)
HK (1)	HK1049170A1 (de)
IL (1)	IL147766A0 (de)
MX (1)	MXPA02000960A (de)
WO (1)	WO2001009186A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7754208B2 (en)	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
CN1312181C (zh) *	2001-02-12	2007-04-25	米德列斯公司	抗Fcα受体(CD89)的人单克隆抗体
US7696320B2 (en)	2004-08-24	2010-04-13	Domantis Limited	Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
ES2376165T3 (es) *	2002-07-15	2012-03-09	F. Hoffmann-La Roche Ag	Tratamiento del c�?ncer con el anticuerpo dirigido contra erbb2 rhumab 2c4.
US20040146948A1 (en) *	2002-10-18	2004-07-29	Centenary Institute Of Cancer Medicine And Cell Biology	Compositions and methods for targeting antigen-presenting cells with antibody single-chain variable region fragments
BG65715B1 (bg) *	2003-09-04	2009-08-31	Чавдар ВАСИЛЕВ	Средство за селективно подтискане на патологични днк - специфични в клетки
CA2616395C (en)	2005-07-25	2016-10-04	Trubion Pharmaceuticals	B-cell reduction using cd37-specific and cd20-specific binding molecules
EP3805269A1 (de)	2006-06-12	2021-04-14	Aptevo Research and Development LLC	Einkettige, multivalente bindungsproteine mit effektorfunktion
KR20110013391A (ko)	2008-04-11	2011-02-09	이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨	Ｃｄ37 면역치료제 및 이작용성 화학치료제와 이의 병용물
KR20140001257A (ko)	2008-05-13	2014-01-06	유니버시티 오브 캔사스	금속 추출 펩타이드(ｍａｐ) 태그 및 관련된 방법
SG11201405468QA (en)	2012-03-14	2014-10-30	Regeneron Pharma	Multispecific antigen-binding molecules and uses thereof
US9187735B2 (en)	2012-06-01	2015-11-17	University Of Kansas	Metal abstraction peptide with superoxide dismutase activity
CN105407920B (zh) *	2013-05-03	2019-12-13	耶鲁大学	靶向癌症、尤其是前列腺癌的合成性抗体模拟化合物(SyAMs)
PL405768A1 (pl) *	2013-10-24	2015-04-27	Celther Polska Spółka Z Ograniczoną Odpowiedzialnością	Zastosowanie agonistów EGFR i HGFR jako leków przeciwnowotworowych działających na komórki nowotworowe o określonym fenotypie
US11129903B2 (en)	2015-07-06	2021-09-28	Regeneron Pharmaceuticals, Inc.	Multispecific antigen-binding molecules and uses thereof
JP7002446B2 (ja)	2015-09-21	2022-03-04	アプティーボリサーチアンドデベロップメントエルエルシー	Ｃｄ３結合ポリペプチド
WO2017190079A1 (en)	2016-04-28	2017-11-02	Regeneron Pharmaceuticals, Inc.	Methods of making multispecific antigen-binding molecules
EP3241847A1 (de) *	2016-05-06	2017-11-08	MAB Discovery GmbH	Her-2-bindende antikörper
WO2018140845A2 (en) *	2017-01-27	2018-08-02	Duke University	Bi-specific antibodies to cd64 and a disease antigen
AU2019370031A1 (en) *	2018-10-29	2021-05-27	Umc Utrecht Holding B.V.	IgA mediated killing of aberrant cells by CD47- SIRPα checkpoint inhibition of neutrophils
SG11202110626SA (en)	2019-03-27	2021-10-28	Umc Utrecht Holding Bv	Engineered iga antibodies and methods of use
WO2022098084A1 (ko) *	2020-11-06	2022-05-12	고려대학교 산학협력단	Fc 알파 수용체 결합 항체

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2067244C (en) *	1989-10-20	2000-12-19	Li Shen	Monoclonal antibody specific for iga receptor
US6018031A (en)	1989-10-20	2000-01-25	Trustees Of Dartmouth College	Binding agents specific for IgA receptor
US5922845A (en) *	1996-07-11	1999-07-13	Medarex, Inc.	Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies

2000
- 2000-07-25 AT AT00948934T patent/ATE373017T1/de not_active IP Right Cessation
- 2000-07-25 AU AU62358/00A patent/AU779116B2/en not_active Ceased
- 2000-07-25 JP JP2001513992A patent/JP4308470B2/ja not_active Expired - Fee Related
- 2000-07-25 WO PCT/US2000/020158 patent/WO2001009186A2/en active IP Right Grant
- 2000-07-25 MX MXPA02000960A patent/MXPA02000960A/es active IP Right Grant
- 2000-07-25 KR KR1020027001270A patent/KR100816958B1/ko not_active IP Right Cessation
- 2000-07-25 DE DE60036388T patent/DE60036388D1/de not_active Expired - Lifetime
- 2000-07-25 CA CA002381565A patent/CA2381565A1/en not_active Abandoned
- 2000-07-25 IL IL14776600A patent/IL147766A0/xx unknown
- 2000-07-25 EP EP00948934A patent/EP1212366B1/de not_active Expired - Lifetime
- 2000-07-25 CN CNB00813684XA patent/CN1268645C/zh not_active Expired - Fee Related
2002
- 2002-12-12 HK HK02108995.6A patent/HK1049170A1/zh unknown
2006
- 2006-12-12 JP JP2006334364A patent/JP2007119485A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
AU6235800A (en)	2001-02-19
JP2007119485A (ja)	2007-05-17
ATE373017T1 (de)	2007-09-15
CN1382157A (zh)	2002-11-27
AU779116B2 (en)	2005-01-06
JP4308470B2 (ja)	2009-08-05
CA2381565A1 (en)	2001-02-08
WO2001009186A2 (en)	2001-02-08
EP1212366A2 (de)	2002-06-12
WO2001009186A3 (en)	2001-05-31
KR20020047103A (ko)	2002-06-21
IL147766A0 (en)	2002-08-14
CN1268645C (zh)	2006-08-09
EP1212366B1 (de)	2007-09-12
JP2003522128A (ja)	2003-07-22
HK1049170A1 (zh)	2003-05-02
KR100816958B1 (ko)	2008-03-26
MXPA02000960A (es)	2002-07-02

Publication	Publication Date	Title
DE60036388D1 (de)	2007-10-25	Therapeutische verbindungen bestehend aus fc rezeptor bindenden wirkstoffen
Neri et al.	2016	Immunocytokines for cancer treatment: past, present and future
Khera et al.	2018	Pharmacokinetic and immunological considerations for expanding the therapeutic window of next-generation antibody–drug conjugates
Cai et al.	2014	Synthetic multivalent glycopeptide‐lipopeptide antitumor vaccines: impact of the cluster effect on the killing of tumor cells
CA2093022C (en)	2005-02-22	Targeted immunostimulation with bispecific reagents
Maruani et al.	2020	A plug-and-play approach for the de novo generation of dually functionalized bispecifics
Prendergast et al.	2017	Novel anti-Sialyl-Tn monoclonal antibodies and antibody-drug conjugates demonstrate tumor specificity and anti-tumor activity
Russell et al.	2004	Cytotoxic properties of immunoconjugates containing melittin-like peptide 101 against prostate cancer: in vitro and in vivo studies
Wolff et al.	1993	Monoclonal antibody homodimers: enhanced antitumor activity in nude mice
Binder et al.	2000	Saturation, competition, and specificity in interaction of heat shock proteins (hsp) gp96, hsp90, and hsp70 with CD11b+ cells
Glaffig et al.	2018	A synthetic MUC1 anticancer vaccine containing mannose ligands for targeting macrophages and dendritic cells
DeVay et al.	2017	Improved lysosomal trafficking can modulate the potency of antibody drug conjugates
Rosenbaum et al.	2020	The fully synthetic glycopeptide MAG-Tn3 therapeutic vaccine induces tumor-specific cytotoxic antibodies in breast cancer patients
WO2006002438A3 (en)	2006-05-04	Human monoclonal antibodies to fc gamma receptor i (cd64)
JP2016509582A5 (de)	2017-01-19
NO331072B1 (no)	2011-09-26	Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
WO2020132366A4 (en)	2020-09-24	T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
KR20200085942A (ko)	2020-07-15	페르투주맙 변이체 및 그의 평가
MX2021010003A (es)	2021-12-10	Anticuerpos anti-mertk de alta afinidad y usos de los mismos.
US20180271997A1 (en)	2018-09-27	Methods and Reagents to Treat Tumor and Cancer
Simpson et al.	2014	Monoclonal antibodies for the therapy of cancer
Gilabert-Oriol et al.	2013	Modified trastuzumab and cetuximab mediate efficient toxin delivery while retaining antibody-dependent cell-mediated cytotoxicity in target cells
Fletcher et al.	2018	Formation of immune complexes with a tetanus-derived B cell epitope boosts human T cell responses to covalently linked peptides in an ex vivo blood loop system
Leal et al.	2015	Preclinical development of an anti-5T4 antibody–drug conjugate: pharmacokinetics in mice, rats, and NHP and tumor/tissue distribution in mice
WO2018231661A1 (en)	2018-12-20	Methods and reagents to treat tumor and cancer

Legal Events

Date	Code	Title	Description
2008-08-14	8332	No legal effect for de